Literature DB >> 20970280

Myocardial remodeling is controlled by myocyte-targeted gene regulation of phosphodiesterase type 5.

Manling Zhang1, Eiki Takimoto, Steven Hsu, Dong I Lee, Takahiro Nagayama, Thomas Danner, Norimichi Koitabashi, Andreas S Barth, Djahida Bedja, Kathleen L Gabrielson, Yibin Wang, David A Kass.   

Abstract

OBJECTIVES: we tested the hypothesis that bi-directional, gene-targeted regulation of cardiomyocyte cyclic guanosine monophosphate-selective phosphodiesterase type 5 (PDE5) influences maladaptive remodeling in hearts subjected to sustained pressure overload.
BACKGROUND: PDE5 expression is up-regulated in human hypertrophied and failing hearts, and its inhibition (e.g., by sildenafil) stimulates protein kinase G activity, suppressing and reversing maladaptive hypertrophy, fibrosis, and contractile dysfunction. Sildenafil is currently being clinically tested for the treatment of heart failure. However, researchers of new studies have questioned the role of myocyte PDE5 and protein kinase G (PKG) to this process, proposing alternative targets and mechanisms.
METHODS: mice with doxycycline-controllable myocyte-specific PDE5 gene expression were generated (medium transgenic [TG] and high TG expression lines) and subjected to sustained pressure overload.
RESULTS: Rest myocyte and heart function, histology, and molecular profiling were normal in both TG lines versus controls at 2 months of age. However, upon exposure to pressure overload (aortic banding), TG hearts developed more eccentric remodeling, maladaptive molecular signaling, depressed function, and amplified fibrosis with up-regulation of tissue growth factor signaling pathways. PKG activation was inhibited in TG myocytes versus controls. After establishing a severe cardiomyopathic state, high-TG mice received doxycycline to suppress PDE5 expression/activity only in myocytes. This in turn enhanced PKG activity and reversed all previously amplified maladaptive responses, despite sustained pressure overload. Sildenafil was also effective in this regard.
CONCLUSIONS: these data strongly support a primary role of myocyte PDE5 regulation to myocardial pathobiology and PDE5 targeting therapy in vivo and reveal a novel mechanism of myocyte-orchestrated extracellular matrix remodeling via PDE5/cyclic guanosine monophosphate-PKG regulatory pathways. Published by Elsevier Inc. All rights reserved.

Entities:  

Mesh:

Substances:

Year:  2010        PMID: 20970280      PMCID: PMC3036840          DOI: 10.1016/j.jacc.2010.08.612

Source DB:  PubMed          Journal:  J Am Coll Cardiol        ISSN: 0735-1097            Impact factor:   24.094


  25 in total

1.  Reengineering inducible cardiac-specific transgenesis with an attenuated myosin heavy chain promoter.

Authors:  Atsushi Sanbe; James Gulick; Mark C Hanks; Qiangrong Liang; Hanna Osinska; Jeffrey Robbins
Journal:  Circ Res       Date:  2003-03-06       Impact factor: 17.367

2.  Cardiac hypertrophy is not amplified by deletion of cGMP-dependent protein kinase I in cardiomyocytes.

Authors:  Robert Lukowski; Sergei D Rybalkin; Florian Loga; Veronika Leiss; Joseph A Beavo; Franz Hofmann
Journal:  Proc Natl Acad Sci U S A       Date:  2010-03-08       Impact factor: 11.205

3.  Cyclic GMP/PKG-dependent inhibition of TRPC6 channel activity and expression negatively regulates cardiomyocyte NFAT activation Novel mechanism of cardiac stress modulation by PDE5 inhibition.

Authors:  Norimichi Koitabashi; Takeshi Aiba; Geoffrey G Hesketh; Janelle Rowell; Manling Zhang; Eiki Takimoto; Gordon F Tomaselli; David A Kass
Journal:  J Mol Cell Cardiol       Date:  2009-12-01       Impact factor: 5.000

Review 4.  Intramyocardial fibroblast myocyte communication.

Authors:  Rahul Kakkar; Richard T Lee
Journal:  Circ Res       Date:  2010-01-08       Impact factor: 17.367

5.  Role of Ca2+/calmodulin-stimulated cyclic nucleotide phosphodiesterase 1 in mediating cardiomyocyte hypertrophy.

Authors:  Clint L Miller; Masayoshi Oikawa; Yujun Cai; Andrew P Wojtovich; David J Nagel; Xiangbin Xu; Haodong Xu; Vince Florio; Sergei D Rybalkin; Joseph A Beavo; Yiu-Fai Chen; Jian-Dong Li; Burns C Blaxall; Jun-ichi Abe; Chen Yan
Journal:  Circ Res       Date:  2009-09-24       Impact factor: 17.367

6.  Pressure-overload magnitude-dependence of the anti-hypertrophic efficacy of PDE5A inhibition.

Authors:  Takahiro Nagayama; Steven Hsu; Manling Zhang; Norimichi Koitabashi; Djahida Bedja; Kathleen L Gabrielson; Eiki Takimoto; David A Kass
Journal:  J Mol Cell Cardiol       Date:  2008-12-29       Impact factor: 5.000

7.  cGMP-hydrolytic activity and its inhibition by sildenafil in normal and failing human and mouse myocardium.

Authors:  Fabrice Vandeput; Judith Krall; Ramzi Ockaili; Fadi N Salloum; Vincent Florio; Jackie D Corbin; Sharron H Francis; Rakesh C Kukreja; Matthew A Movsesian
Journal:  J Pharmacol Exp Ther       Date:  2009-06-22       Impact factor: 4.030

Review 8.  Cyclic GMP signaling in cardiovascular pathophysiology and therapeutics.

Authors:  Emily J Tsai; David A Kass
Journal:  Pharmacol Ther       Date:  2009-03-21       Impact factor: 12.310

9.  PDE5A suppression of acute beta-adrenergic activation requires modulation of myocyte beta-3 signaling coupled to PKG-mediated troponin I phosphorylation.

Authors:  Dong I Lee; Susan Vahebi; Carlo Gabriele Tocchetti; Lili A Barouch; R John Solaro; Eiki Takimoto; David A Kass
Journal:  Basic Res Cardiol       Date:  2010-01-27       Impact factor: 17.165

10.  cGMP catabolism by phosphodiesterase 5A regulates cardiac adrenergic stimulation by NOS3-dependent mechanism.

Authors:  Eiki Takimoto; Hunter C Champion; Diego Belardi; Javid Moslehi; Marco Mongillo; Evanthia Mergia; David C Montrose; Takayoshi Isoda; Kate Aufiero; Manuela Zaccolo; Wolfgang R Dostmann; Carolyn J Smith; David A Kass
Journal:  Circ Res       Date:  2004-12-02       Impact factor: 17.367

View more
  34 in total

Review 1.  Phenotype-Specific Treatment of Heart Failure With Preserved Ejection Fraction: A Multiorgan Roadmap.

Authors:  Sanjiv J Shah; Dalane W Kitzman; Barry A Borlaug; Loek van Heerebeek; Michael R Zile; David A Kass; Walter J Paulus
Journal:  Circulation       Date:  2016-07-05       Impact factor: 29.690

Review 2.  Nitric oxide-cyclic GMP signaling in stem cell differentiation.

Authors:  Kalpana Mujoo; Joshua S Krumenacker; Ferid Murad
Journal:  Free Radic Biol Med       Date:  2011-10-06       Impact factor: 7.376

Review 3.  Heart failure in single right ventricle congenital heart disease: physiological and molecular considerations.

Authors:  Anastacia M Garcia; Jonathan-Thomas Beatty; Stephanie J Nakano
Journal:  Am J Physiol Heart Circ Physiol       Date:  2020-02-28       Impact factor: 4.733

Review 4.  Protein kinase G I and heart failure: Shifting focus from vascular unloading to direct myocardial antiremodeling effects.

Authors:  Qingwu Kong; Robert M Blanton
Journal:  Circ Heart Fail       Date:  2013-11       Impact factor: 8.790

Review 5.  Therapeutic potential of PDE modulation in treating heart disease.

Authors:  Walter Knight; Chen Yan
Journal:  Future Med Chem       Date:  2013-09       Impact factor: 3.808

6.  Prevention of PKG-1α Oxidation Suppresses Antihypertrophic/Antifibrotic Effects From PDE5 Inhibition but not sGC Stimulation.

Authors:  Taishi Nakamura; Guangshuo Zhu; Mark J Ranek; Kristen Kokkonen-Simon; Manling Zhang; Grace E Kim; Kenichi Tsujita; David A Kass
Journal:  Circ Heart Fail       Date:  2018-03       Impact factor: 8.790

7.  Phosphodiesterase-5 Is Elevated in Failing Single Ventricle Myocardium and Affects Cardiomyocyte Remodeling In Vitro.

Authors:  Anastacia M Garcia; Stephanie J Nakano; Anis Karimpour-Fard; Karin Nunley; Penny Blain-Nelson; Natalie M Stafford; Brian L Stauffer; Carmen C Sucharov; Shelley D Miyamoto
Journal:  Circ Heart Fail       Date:  2018-09       Impact factor: 8.790

8.  Impact of sildenafil on echocardiographic indices of myocardial performance after the Fontan operation.

Authors:  David J Goldberg; Benjamin French; Anita L Szwast; Michael G McBride; Bradley S Marino; Nicole Mirarchi; Brian D Hanna; Gil Wernovsky; Stephen M Paridon; Jack Rychik
Journal:  Pediatr Cardiol       Date:  2012-02-14       Impact factor: 1.655

Review 9.  Old dog, new tricks: novel cardiac targets and stress regulation by protein kinase G.

Authors:  Peter P Rainer; David A Kass
Journal:  Cardiovasc Res       Date:  2016-06-13       Impact factor: 10.787

10.  Cardiac Adenylyl Cyclase and Phosphodiesterase Expression Profiles Vary by Age, Disease, and Chronic Phosphodiesterase Inhibitor Treatment.

Authors:  Stephanie J Nakano; Juliana Sucharov; Robert van Dusen; Mackenzie Cecil; Karin Nunley; Sean Wickers; Anis Karimpur-Fard; Brian L Stauffer; Shelley D Miyamoto; Carmen C Sucharov
Journal:  J Card Fail       Date:  2016-07-15       Impact factor: 5.712

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.